Concomitant Use of Proton Pump Inhibitors and Thienopyridines in Acute Coronary Syndrome Patients Followed Up in the Intensive Cardiac Care Unit

Mustafa Ozan GÜRSOY; Mustafa YILDIZ

Journals / Koşuyolu Heart Journal / 2016 / Cilt: 19 - Sayı: 1

Concomitant Use of Proton Pump Inhibitors and Thienopyridines in Acute Coronary Syndrome Patients Followed Up in the Intensive Cardiac Care Unit

Koroner Yoğun Bakımda Yatan Akut Koroner Sendrom Hastalarında Tienopiridin ve Proton Pompa İnhibitör Kullanımı

Mustafa Ozan GÜRSOY

Mustafa YILDIZ

Journal: Koşuyolu Heart Journal
Issue: 2016 · Cilt: 19 - Sayı: 1
Pages: 37–39
Publication Date: 2016-04-04
DOI: —

🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.

DergiPark Record ↗

✨

AI Summary & Key Takeaways

AI Insight

⚡ TL;DR(Too Long; Didn't Read)

This study summarizes the well-known interaction of PPIs and thienopyridines in ACS patients on the basis of previous literature.

📌 3 Key Takeaways

🎯

Objective & Hypothesis: Patients with an established diagnosis of acute coronary syndrome (ACS) require dual antiplatelet therapy, which is most commonly composed of asetil salicylic acid and thienopyridines.

📊

Key Findings & Data:Some studies found increased cardiovascular risk after the use of PPIs, whereas others did not detect any clinically significant risk.

💡

Conclusion & Impact:This study summarizes the well-known interaction of PPIs and thienopyridines in ACS patients on the basis of previous literature.

🔬Design:Research Article

📍Scope:Comprehensive Sample

⚙️Variables:Tienopiridin · proton pompası inhibitörü · akut koroner sendrom

Abstract

Patients with an established diagnosis of acute coronary syndrome (ACS) require dual antiplatelet therapy, which is most commonly composed of asetil salicylic acid and thienopyridines. This group of patients usually comprises older subjects with comorbid diseases and need gastric protection for potential gastrointestinal bleeding. At the time of admission in intensive cardiac care units, proton pump inhibitors (PPIs) are usually used for standard medical treatment. Several studies have evaluated the potential interaction between PPIs and thienopyridines; however, they have reported conflicting results. Some studies found increased cardiovascular risk after the use of PPIs, whereas others did not detect any clinically significant risk. The rational use of concomitant thienopyridines and PPIs should be decided after weighing their risks against their benefits. The use of latest PPIs such as pantoprazole seems to be safe in ACS patients. This study summarizes the well-known interaction of PPIs and thienopyridines in ACS patients on the basis of previous literature.

Özet

Akut koroner sendrom (AKS) tanısı alan hastalarda genellikle ikili antiplatelet tedavi uygulanmaktadır ki en sık olarak asetilsalisilik asit ve tienopiridinler kullanılır. Bu grup hastalar genellikle daha yaşlıdır ve komorbid hastalıklara sahiptirler; bu nedenle olası gastrointestinal kanama riski nedeniyle gastrik korumaya ihtiyaç duyarlar. Koroner yoğun bakımda yatan hastalara standart tedaviye genellikle proton pompa inhibitörleri (PPI) eklenir. Şu ana kadar PPI ile tienopiridin grubu ilaçlar arasındaki potansiyel etkileşimi değerlendiren birçok çalışma mevcuttur. Çelişkili sonuçlar bulunmuştur; bazı çalışmalarda PPI kullanımı sonrası artmış kardiyovasküler risk görülürken, bazılarında anlamlı klinik fark saptanmamıştır. PPI ile tienopiridin grubu ilaçların birlikte kullanımına kar-zarar oranı göz önünde bulundurularak karar verilmelidir. Daha sonradan piyasaya sürülen PPI’lar (pantoprazol gibi) AKS hastalarında daha güvenilir gözükmektedir. Bu yazıda geçmiş literatür ışığında AKS hastalarında PPI ve tienopiridinlerin birlikte kullanılmasında ortaya çıkabilen bu iyi bilinen ilaç etkileşimi özetlenmektedir.

Keywords

Tienopiridin proton pompası inhibitörü akut koroner sendrom ilaç etkileşimleri Thienopyridine proton pump inhibitors acute coronary syndrome drug interactions

🔖

Cite This Article

GÜRSOY, M. O., YILDIZ, M. (2016). Concomitant Use of Proton Pump Inhibitors and Thienopyridines in Acute Coronary Syndrome Patients Followed Up in the Intensive Cardiac Care Unit. Koşuyolu Heart Journal, Cilt: 19 - Sayı: 1, 37–39. https://ajindex.com/articles/101288

📄 Full Text PDF Viewer

Open in New Tab ↗

↗New Tab

📄

PDF görüntüleyici hazırlanıyor...

References (13)

Fuster V, Moreno PR, Fayad ZA, Corti R, Badimon JJ. Atherothrombosis and high-risk plaque: part I: evolving concepts. J Am Coll Cardiol 2005;46:937-54
CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee. Lancet 1996;348:1329-39
Wiviott SD, Braunwald E, McCabe CH, Montalescot G, Ruzyllo W, Gottlieb S, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007;357:2001-15
Wallentin L, Becker RC, Budaj A, Cannon CP, Emanuelsson H, Held C, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009;361:1045-57
Kazui M, Nishiya Y, Ishizuka T, Hagihara K, Farid NA, Okazaki O, et al. IdentiÞcation of the human cytochrome P450 enzymes involved in the two oxidative steps in the bioactivation of clopidogrel to its pharmacologically active metabolite. Drug Metab Dispos 2010;38:92-9
Mackenzie IS, Coughtrie MWH, MacDonald TM, Wei L. Antiplatelet drug interactions. J Intern Med 2010;268:516-29
Ho PM, Maddox TM, Wang L, Fihn SD, Jesse RL, Peterson ED, et al. Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome. JAMA 2009;301:937-44
Khalique SC, Cheng-Lai A. Drug interaction between clopidogrel and proton pump inhibitors. Cardiol Rev 2009;17:198-200
Gilard M, Arnaud B, Le Gal G, Abgrall JF, Boschat J. Inþuence of omeprazole on the antiplatelet action of clopidogrel associated to aspirin. J Thromb Haemost 2006;4:2508-9
Bhatt DL, Scheiman J, Abraham NS, Antman EM, Chan FK, Furberg CD, et al. American College of Cardiology Foundation; American College of Gastroenterology; American Heart Association. ACCF/ ACG/AHA 2008 Expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use. Am J Gastroenterol 2009;103:2890-907
Zuern CS, Geisler T, Lutilsky N, Winter S, Schwab M, Gawaz M. Effect of comedication with proton pump inhibitors (PPIs) on post-interventional residual platelet aggregation in patients undergoing coronary stenting treated by dual antiplatelet therapy. Thromb Res 2010;125:e51-4
Sibbing D, Morath T, Stegherr J, Braun S, Vogt W, Hadamitzky M, et al. Impact of proton pump inhibitors on the antiplatelet effects of clopidogrel. Thromb Haemost 2009;101:714-9
Gremmel T, Steiner S, Seidinger D, Koppensteiner R, Panze